PolyPid (PYPD) awards CFO 49,000 stock options at $4.46
Rhea-AI Filing Summary
PolyPid Ltd. reported that Chief Financial Officer Jonathan Missulawin received a grant of stock options for 49,000 Ordinary Shares on May 11, 2026. The options have an exercise price of $4.46 per share, an exercise date of August 11, 2026, and expire on May 11, 2036. According to the vesting terms, they vest on a quarterly basis beginning May 11, 2026 until May 11, 2030, leaving him with 49,000 options outstanding.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Missulawin Jonathan
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) F1 | 49,000 | $4.46 | $219K |
Holdings After Transaction:
Stock option (right to buy) — 49,000 shares (Direct)
Footnotes (1)
- F1. The options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030.
Key Figures
Stock options granted: 49,000 options
Exercise price: $4.46 per share
Underlying Ordinary Shares: 49,000 shares
+4 more
7 metrics
Stock options granted
49,000 options
Grant to CFO Jonathan Missulawin on 2026-05-11
Exercise price
$4.46 per share
Exercise price for the 49,000 stock options
Underlying Ordinary Shares
49,000 shares
Shares underlying the granted stock options
Total options held after grant
49,000 options
Directly held derivative securities following the reported transaction
Exercise date
2026-08-11
Reported exercise date for the granted options
Expiration date
2036-05-11
Expiration date of the stock options
Vesting period
May 11, 2026–May 11, 2030
Options vest quarterly over this four-year period
Key Terms
Stock option (right to buy), exercise date, expiration date, vest on a quarterly basis
4 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise date financial
"exercise_date: 2026-08-11 is the exercise date"
expiration date financial
"expiration_date: 2036-05-11 is the expiration date"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest on a quarterly basis financial
"The options vest on a quarterly basis beginning May 11, 2026"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did PolyPid (PYPD) report for its CFO?
PolyPid reported a grant to CFO Jonathan Missulawin of stock options covering 49,000 Ordinary Shares. The award was dated May 11, 2026, with an exercise price of $4.46 per share, an exercise date of August 11, 2026, and an expiration date of May 11, 2036.
What are the key terms of the PolyPid (PYPD) stock options granted to the CFO?
The CFO received 49,000 stock options with an exercise price of $4.46 per share. They have an exercise date of August 11, 2026 and expire on May 11, 2036, providing a long-dated incentive linked to PolyPid’s Ordinary Shares.
How do the PolyPid (PYPD) CFO’s stock options vest?
According to the terms, the options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030. This creates a four-year vesting schedule, with portions of the 49,000 options becoming exercisable each quarter over that period.
How many PolyPid (PYPD) options does the CFO hold after this grant?
After the transaction, the CFO is reported to beneficially hold 49,000 stock options directly. These options are linked to 49,000 underlying Ordinary Shares, all from this single grant dated May 11, 2026.
Was the PolyPid (PYPD) CFO’s option grant made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the transaction is categorized as a grant or award, not an open-market trade executed under a pre-arranged trading plan.